Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

被引:321
作者
Eisenkop, SM
Spirtos, NM
Friedman, RL
Lin, WCM
Pisani, AL
Perticucci, S
机构
[1] Womens Canc Ctr, Tarzana, CA 91356 USA
[2] Womens Canc Ctr, Palo Alto, CA 94304 USA
[3] Womens Canc Ctr, Los Angeles, CA 90027 USA
[4] Womens Canc Ctr, San Diego, CA 92120 USA
[5] Womens Canc Ctr, Bakersfield, CA 93309 USA
关键词
D O I
10.1016/S0090-8258(03)00278-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The purpose of this study was to determine the relative influences of the extent of disease present before surgery and completeness of cytoreduction on survival for patients with advanced ovarian cancer. Methods. Patients (408) with stage IIIC epithelial ovarian cancer had cytoreductive surgery before systemic platinum-based combination chemotherapy. A ranking system (0-3) was devised to prospectively quantify the extent of disease involving: (1) right upper quadrant (diaphragm/hepatic, and adjacent peritoneal surfaces), (2) left upper quadrant (omentum/gastro-colic ligament, spleen, stomach, transverse colon, splenic flexure of colon), (3) pelvis (reproductive organs, recto-sigmoid, pelvic peritoneum), (4) retroperitoneum (pelvic/aortic nodes), and (5) central abdomen (small bowel, ascending/descending colon, mesentery, anterior abdominal wall, pericolic gutters). Survival was analyzed (log rank and Cox regression) on the basis of the rankings at these anatomic regions, the sum of intraabdominal rankings, and the cytoreductive outcome. Results. Overall median and estimated 5-year survivals were 58.2 months and 49%. On univariate analysis, the central abdominal (P = 0.008) and left upper quadrant (P = 0.03) rankings, the sum of rankings (P less than or equal to 0.01), and the cytoreductive outcome (P ! 0.0001) influenced survival (log rank). Survival was independently (stepwise Cox model) influenced by the sum of rankings (0-5, RR 1.00; 6-10, RR 1.24; 11-15, RR 1.44; P = 0.05), and completeness of cytoreduction (visibly disease-free, RR 1.00; less than or equal to 1 cm residual, RR 2.32; >1 cm residual, RR 2.98; P = 0.001). Conclusions. Cytoreduction to a visibly disease-free outcome has a more significant influence on survival than the extent of metastatic disease present before surgery. Operative efforts should not be abbreviated on the hypothesis that extensive disease at specific anatomic regions precludes long-term survival. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:390 / 396
页数:7
相关论文
共 29 条
  • [1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
    Alberts, DS
    Liu, PY
    Hannigan, EV
    OToole, R
    Williams, SD
    Young, JA
    Franklin, EW
    ClarkePearson, DL
    Malviya, VK
    DuBeshter, B
    Adelson, MD
    Hoskins, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) : 1950 - 1955
  • [2] BENEDETTIPANICI P, 1991, INT J GYNECOL CANCER, V133, P1
  • [3] Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator
    Bristow, RE
    Montz, FJ
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 83 (01) : 39 - 48
  • [4] Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    Bristow, RE
    Tomacruz, RS
    Armstrong, DK
    Trimble, EL
    Montz, FJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1248 - 1259
  • [5] Identification of prognostic factors in advanced epithelial ovarian carcinoma
    Chi, DS
    Liao, JB
    Leon, LF
    Venkatraman, ES
    Hensley, ML
    Bhaskaran, D
    Hoskins, WJ
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 82 (03) : 532 - 537
  • [6] Critique of surgical cytoreduction in advanced ovarian cancer
    Covens, AL
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 78 (03) : 269 - 274
  • [7] DEBULKING SURGERY FOR OVARIAN-CANCER WITH THE CAVITRON ULTRASONIC SURGICAL ASPIRATOR (CUSA) - A PRELIMINARY-REPORT
    DEPPE, G
    MALVIYA, VK
    MALONE, JM
    [J]. GYNECOLOGIC ONCOLOGY, 1988, 31 (01) : 223 - 226
  • [8] PERITONEAL IMPLANT ELIMINATION DURING CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER - IMPACT ON SURVIVAL
    EISENKOP, SM
    NALICK, RH
    WANG, HJ
    TENG, NNH
    [J]. GYNECOLOGIC ONCOLOGY, 1993, 51 (02) : 224 - 229
  • [9] Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival?
    Eisenkop, SM
    Spirtos, NM
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 82 (03) : 435 - 441
  • [10] Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study
    Eisenkop, SM
    Friedman, RL
    Wang, HJ
    [J]. GYNECOLOGIC ONCOLOGY, 1998, 69 (02) : 103 - 108